These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 29403308)

  • 1. The relationship between the PD-1/PD-L1 pathway and DNA mismatch repair in cervical cancer and its clinical significance.
    Feng YC; Ji WL; Yue N; Huang YC; Ma XM
    Cancer Manag Res; 2018; 10():105-113. PubMed ID: 29403308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A subset of patients with MSS/MSI-low-colorectal cancer showed increased CD8(+) TILs together with up-regulated IFN-γ.
    Kikuchi T; Mimura K; Okayama H; Nakayama Y; Saito K; Yamada L; Endo E; Sakamoto W; Fujita S; Endo H; Saito M; Momma T; Saze Z; Ohki S; Kono K
    Oncol Lett; 2019 Dec; 18(6):5977-5985. PubMed ID: 31788072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor microenvironment classification based on T-cell infiltration and PD-L1 in patients with mismatch repair-proficient and -deficient colorectal cancer.
    Liu S; Kong P; Wang X; Yang L; Jiang C; He W; Quan Q; Huang J; Xie Q; Xia X; Zhang B; Xia L
    Oncol Lett; 2019 Feb; 17(2):2335-2343. PubMed ID: 30675299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PMS2 Expression With Combination of PD-L1 and TILs for Predicting Survival of Esophageal Squamous Cell Carcinoma.
    Jiang D; Song Q; Wei X; Yu Z; Liu Y; Wang H; Wang X; Huang J; Su J; Hong Y; Xu Y; Xu C; Hou Y
    Front Oncol; 2022; 12():897527. PubMed ID: 35865481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy in Penile Squamous Cell Carcinoma: Present or Future? Multi-Target Analysis of Programmed Cell Death Ligand 1 Expression and Microsatellite Instability.
    Montella M; Sabetta R; Ronchi A; De Sio M; Arcaniolo D; De Vita F; Tirino G; Caputo A; D'Antonio A; Fiorentino F; Facchini G; Lauro GD; Perdonà S; Ventriglia J; Aquino G; Feroce F; Borges Dos Reis R; Neder L; Brunelli M; Franco R; Zito Marino F
    Front Med (Lausanne); 2022; 9():874213. PubMed ID: 35592855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endometrial Tumors with MSI-H and dMMR Share a Similar Tumor Immune Microenvironment.
    Song Y; Gu Y; Hu X; Wang M; He Q; Li Y
    Onco Targets Ther; 2021; 14():4485-4497. PubMed ID: 34429613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Solid-type poorly differentiated adenocarcinoma of the stomach: A characteristic morphology reveals a distinctive immunoregulatory tumor microenvironment.
    Kawatoko S; Kohashi K; Torisu T; Sasaki T; Umekita S; Oki E; Nakamura M; Kitazono T; Oda Y
    Pathol Res Pract; 2022 Oct; 238():154124. PubMed ID: 36137397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mismatch repair-deficient colorectal cancer: a model of immunogenic and immune cell-rich tumor despite nonsignificant programmed cell death ligand-1 expression in tumor cells.
    Le Flahec G; Badic B; Guibourg B; Doucet L; Bail JP; Marcorelles P; Schick U; Uguen A
    Hum Pathol; 2018 Feb; 72():135-143. PubMed ID: 29208565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can evaluation of mismatch repair defect and TILs increase the number of triple-negative breast cancer patients eligible for immunotherapy?
    Özcan D; Lade-Keller J; Tramm T
    Pathol Res Pract; 2021 Oct; 226():153606. PubMed ID: 34530255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High density of cytotoxic T-lymphocytes is linked to tumoral PD-L1 expression regardless of the mismatch repair status in colorectal cancer.
    Möller K; Blessin NC; Höflmayer D; Büscheck F; Luebke AM; Kluth M; Hube-Magg C; Zalewski K; Hinsch A; Neipp M; Mofid H; Lárusson H; Daniels T; Isbert C; Coerper S; Ditterich D; Rupprecht H; Goetz A; Bernreuther C; Sauter G; Uhlig R; Wilczak W; Simon R; Steurer S; Minner S; Burandt E; Krech T; Perez D; Izbicki JR; Clauditz TS; Marx AH
    Acta Oncol; 2021 Sep; 60(9):1210-1217. PubMed ID: 34092167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach.
    Luchini C; Bibeau F; Ligtenberg MJL; Singh N; Nottegar A; Bosse T; Miller R; Riaz N; Douillard JY; Andre F; Scarpa A
    Ann Oncol; 2019 Aug; 30(8):1232-1243. PubMed ID: 31056702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA mismatch repair system regulates the expression of PD-L1 through DNMTs in cervical cancer.
    Guo F; Lu R; Kong W; Anwar M; Feng Y
    Cancer Cell Int; 2024 Jan; 24(1):25. PubMed ID: 38200495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicopathologic characteristics, tumor infiltrating lymphocytes and programed cell death ligand-1 expression in 162 endometrial carcinomas with deficient mismatch repair function.
    Chavez JA; Wei L; Suarez AA; Parwani AV; Li Z
    Int J Gynecol Cancer; 2019 Jan; 29(1):113-118. PubMed ID: 30640692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Difference analysis of somatic mutations between deficient mismatch repair and proficient mismatch repair gene related with colorectal cancer].
    Tang XJ; Yang MY; Zhu LZ; Xu D; Yuan Y
    Zhonghua Zhong Liu Za Zhi; 2021 Oct; 43(10):1088-1093. PubMed ID: 34695900
    [No Abstract]   [Full Text] [Related]  

  • 15. Heterogeneity of PD-L1 expression and CD8 lymphocyte infiltration in metastatic colorectal cancer and their prognostic significance.
    Xin H; Zhou C; Wang G; Liu Y; Zhang J; Liu Y; Li B; Zhang J; Su M; Li Z; Wang G
    Heliyon; 2023 Feb; 9(2):e13048. PubMed ID: 36814622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of mismatch-repair deficiency on the colorectal cancer immune microenvironment.
    Zhang Y; Sun Z; Mao X; Wu H; Luo F; Wu X; Zhou L; Qin J; Zhao L; Bai C
    Oncotarget; 2017 Oct; 8(49):85526-85536. PubMed ID: 29156738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD169
    Saito Y; Fujiwara Y; Miyamoto Y; Ohnishi K; Nakashima Y; Tabata Y; Baba H; Komohara Y
    Cancer Med; 2023 May; 12(9):10199-10211. PubMed ID: 36846928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of Programmed Cell Death Ligand-1 and Mismatch Repair Status in Endometrial Carcinomas.
    Rajendran M; Rao M; Elhence PA; Bharti JN; Singh P; Yadav G; Nalwa A; Goyal AD
    J Midlife Health; 2023; 14(2):81-86. PubMed ID: 38029026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of survival advantage for deficient mismatch repair in patients with advanced colorectal cancer may be caused by changes in prognostic value of CD8+T cell.
    Wang B; Li F; Guo L; Lu S; Ma J; Ma Y; Meng Y; Wang J; Zhou X; Fu W
    World J Surg Oncol; 2020 Aug; 18(1):196. PubMed ID: 32767974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of PD-1/PD-L1 Inhibitor as Single-Agent Immunotherapy in Endometrial Cancer: A Systematic Review and Meta-Analysis.
    Mamat Yusof MN; Chew KT; Hafizz AMHA; Abd Azman SH; Ab Razak WS; Hamizan MR; Kampan NC; Shafiee MN
    Cancers (Basel); 2023 Aug; 15(16):. PubMed ID: 37627060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.